Diaceutics (LON:DXRX) Reaches New 12-Month Low – What’s Next?

Diaceutics PLC (LON:DXRX) reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 125 and last traded at GBX 127, with a volume of 224054 shares. The stock had previously closed at GBX 128.

Analyst Ratings Changes

Separately, Canaccord Genuity Group increased their price objective on shares of Diaceutics from GBX 215 to GBX 216 and gave the company a “buy” rating in a research report on Thursday, June 4th. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of GBX 215.50.

Diaceutics Stock Down 0.8%

The company has a debt-to-equity ratio of 2.85, a quick ratio of 9.92 and a current ratio of 3.43. The firm has a market cap of £107.48 million, a price-to-earnings ratio of 1,154.55 and a beta of 0.89. The firm has a 50-day moving average price of GBX 143.48 and a two-hundred day moving average price of GBX 153.46.

Diaceutics (LON:DXRX) last posted its earnings results on Tuesday, May 26th. The company reported GBX 11 earnings per share for the quarter. The firm had revenue of GBX 3,844 million during the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. On average, sell-side analysts forecast that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.